PTCT [NASD]
PTC Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.38 Insider Own0.70% Shs Outstand71.22M Perf Week9.31%
Market Cap2.99B Forward P/E- EPS next Y-3.80 Insider Trans-10.82% Shs Float69.15M Perf Month61.13%
Income-522.00M PEG- EPS next Q-1.24 Inst Own- Short Float8.13% Perf Quarter5.62%
Sales569.40M P/S5.25 EPS this Y-12.00% Inst Trans-1.22% Short Ratio7.10 Perf Half Y9.92%
Book/sh-1.27 P/B- EPS next Y29.40% ROA-26.80% Target Price47.56 Perf Year1.60%
Cash/sh8.61 P/C5.09 EPS next 5Y-9.51% ROE-983.20% 52W Range25.01 - 45.80 Perf YTD9.92%
Dividend- P/FCF- EPS past 5Y-12.20% ROI-31.90% 52W High-6.31% Beta0.63
Dividend %- Quick Ratio1.60 Sales past 5Y45.50% Gross Margin94.10% 52W Low71.57% ATR2.18
Employees1252 Current Ratio1.60 Sales Q/Q26.10% Oper. Margin-63.70% RSI (14)73.62 Volatility4.38% 6.52%
OptionableYes Debt/Eq- EPS Q/Q2.90% Profit Margin-91.70% Rel Volume1.19 Prev Close43.78
ShortableYes LT Debt/Eq- EarningsMay 03 AMC Payout- Avg Volume791.71K Price42.91
Recom2.50 SMA2028.72% SMA5029.56% SMA20014.43% Volume945,663 Change-1.99%
Apr-04-22Resumed Cantor Fitzgerald Overweight $64 → $63
Oct-18-21Downgrade BofA Securities Neutral → Underperform $38
Apr-26-21Resumed Credit Suisse Neutral $54
Mar-29-21Upgrade RBC Capital Mkts Underperform → Sector Perform $47
Feb-12-21Downgrade BofA Securities Buy → Neutral
Jan-05-21Upgrade Citigroup Neutral → Buy $67 → $85
Nov-30-20Downgrade RBC Capital Mkts Sector Perform → Underperform $45
Oct-30-20Downgrade Citigroup Buy → Neutral
Oct-28-20Initiated UBS Neutral $55
Oct-07-20Upgrade JP Morgan Neutral → Overweight $71
Aug-25-20Initiated Raymond James Outperform $63
Apr-09-20Upgrade Citigroup Neutral → Buy $71 → $67
Feb-20-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-20-20Downgrade Citigroup Buy → Neutral $55 → $71
Nov-12-19Initiated SunTrust Buy $78
May-13-19Upgrade BofA/Merrill Neutral → Buy $43 → $49
Apr-11-19Initiated Bernstein Outperform $48
Oct-03-18Upgrade BofA/Merrill Underperform → Neutral
Oct-01-18Initiated Cantor Fitzgerald Overweight $66
Jul-19-18Initiated Credit Suisse Outperform $49
Jun-23-22 04:11PM  
Jun-20-22 04:00PM  
Jun-09-22 08:00AM  
Jun-06-22 08:00AM  
Jun-03-22 08:00AM  
Jun-01-22 09:49AM  
May-31-22 01:00AM  
May-24-22 03:13PM  
May-20-22 01:50PM  
08:08AM  
May-03-22 05:45PM  
04:01PM  
Apr-29-22 04:30PM  
Apr-26-22 03:01PM  
Apr-19-22 08:00AM  
Apr-14-22 08:30AM  
Apr-13-22 09:29AM  
Apr-08-22 04:23PM  
Apr-04-22 07:32AM  
Mar-30-22 04:00PM  
Mar-14-22 05:18AM  
Mar-11-22 08:00AM  
Feb-23-22 08:00AM  
Feb-22-22 05:25PM  
04:01PM  
Feb-18-22 08:46AM  
Feb-15-22 03:01PM  
Feb-08-22 08:00AM  
Jan-25-22 01:00AM  
Jan-18-22 08:00AM  
Jan-13-22 04:30PM  
08:00AM  
04:16AM  
Jan-11-22 08:19AM  
Jan-10-22 07:00AM  
Jan-04-22 08:00AM  
Jan-03-22 08:00AM  
Dec-23-21 07:39AM  
Dec-20-21 08:00AM  
Dec-15-21 03:38PM  
Dec-09-21 07:39AM  
Dec-06-21 09:13AM  
Dec-02-21 04:30PM  
Nov-16-21 08:00AM  
Nov-08-21 12:51PM  
Oct-29-21 12:31AM  
Oct-28-21 05:15PM  
04:00PM  
Oct-26-21 08:00AM  
Oct-25-21 09:56PM  
08:00AM  
Oct-21-21 03:03PM  
Oct-14-21 08:58AM  
08:30AM  
Oct-11-21 08:00AM  
Oct-06-21 08:16PM  
Sep-29-21 04:30PM  
12:30PM  
08:00AM  
Sep-20-21 04:30PM  
08:30AM  
Sep-13-21 08:00AM  
Sep-07-21 08:00AM  
Aug-27-21 08:00AM  
Aug-24-21 07:06AM  
Aug-23-21 04:30PM  
09:00AM  
Aug-20-21 04:30PM  
Aug-10-21 04:34AM  
Jul-29-21 04:00PM  
Jul-28-21 05:00PM  
Jul-22-21 03:03PM  
Jul-19-21 12:58PM  
Jul-15-21 08:00AM  
Jun-24-21 08:00AM  
Jun-23-21 08:00AM  
Jun-15-21 04:30PM  
Jun-11-21 07:10AM  
01:00AM  
Jun-09-21 08:00AM  
May-27-21 10:23AM  
May-26-21 08:00AM  
May-19-21 08:00AM  
May-17-21 08:00AM  
May-04-21 05:25PM  
04:01PM  
02:30PM  
Apr-30-21 06:29AM  
Apr-27-21 08:00AM  
Apr-24-21 05:08PM  
Apr-20-21 08:00AM  
Apr-19-21 04:30PM  
Apr-15-21 01:00AM  
Apr-14-21 08:00AM  
Apr-12-21 07:35AM  
Apr-07-21 09:30AM  
08:50AM  
Apr-01-21 08:00AM  
Mar-30-21 07:05AM  
01:00AM  
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Svoronos DawnDirectorJun 09Sale27.2073820,07429,017Jun 10 04:06 PM
Peltz Stuart WalterCHIEF EXECUTIVE OFFICERJun 07Sale26.8340710,91938,239Jun 09 04:03 PM
Klein Matthew B.CHIEF OPERATING OFFICERApr 19Sale42.5289738,13656,564Apr 21 04:03 PM
Pauwels EricCHIEF BUSINESS OFFICERApr 19Sale42.5282234,94749,772Apr 21 04:02 PM
Peltz Stuart WalterCHIEF EXECUTIVE OFFICERApr 14Sale45.28823,71338,646Apr 15 04:04 PM
Boulding Mark ElliottEXEC. VP AND CLOApr 13Option Exercise11.232,27625,55963,386Apr 15 04:02 PM
Boulding Mark ElliottEXEC. VP AND CLOApr 13Sale45.172,276102,81161,110Apr 15 04:02 PM
Boulding Mark ElliottEXEC. VP AND CLOApr 05Option Exercise11.2355661,115Apr 07 04:03 PM
Boulding Mark ElliottEXEC. VP AND CLOApr 05Sale45.00522561,110Apr 07 04:03 PM
Hill Emily LuisaCHIEF FINANCIAL OFFICERMar 31Sale37.787,910298,82429,259Apr 01 04:20 PM
Boulding Mark ElliottExec. VP and CLOFeb 10Option Exercise17.1517,935307,53776,763Feb 11 04:11 PM
Boulding Mark ElliottExec. VP and CLOFeb 10Sale45.0317,935807,55961,110Feb 11 04:11 PM
Utter Christine MarieSVP, Finance & CAOFeb 02Sale40.3870728,54925,405Feb 03 04:59 PM
Boulding Mark ElliottExec. VP and CLOFeb 01Sale40.0077931,16261,110Feb 03 04:57 PM
Hill Emily LuisaChief Financial OfficerFeb 01Sale40.0055322,12137,169Feb 03 04:58 PM
Pauwels EricChief Business OfficerFeb 01Sale40.0036714,68150,594Feb 03 04:58 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale40.0028211,28138,728Feb 03 04:58 PM
Peltz Stuart WalterChief Executive OfficerFeb 01Sale40.001,96178,444120,485Feb 03 04:58 PM
Utter Christine MarieSVP, Finance & CAOFeb 01Sale40.0031312,52126,112Feb 03 04:59 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale40.00271,0802,420Feb 03 04:57 PM
Almstead Neil GregoryChief Technical Ops OfficerFeb 01Sale40.0060524,20148,853Feb 03 04:57 PM
Hill Emily LuisaChief Financial OfficerJan 25Sale39.312118,29537,722Jan 27 04:01 PM
Pauwels EricChief Business OfficerJan 25Sale39.3135914,11450,961Jan 27 04:02 PM
Peltz Stuart WalterChief Executive OfficerJan 25Sale39.3133012,97439,010Jan 27 04:02 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 25Sale39.31431,6912,447Jan 27 04:01 PM
Utter Christine MarieSVP, Finance & CAOJan 18Option Exercise18.0110,000180,10036,425Jan 20 04:50 PM
Utter Christine MarieSVP, Finance & CAOJan 18Sale43.9411,428502,11826,425Jan 20 04:50 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale38.52451,7341,710Jan 11 04:20 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 07Sale38.5275629,12535,058Jan 11 04:20 PM
Utter Christine MarieSVP, Finance & CAOJan 07Sale38.5274728,77816,253Jan 11 04:21 PM
Boulding Mark ElliottExec. VP and CLOJan 07Sale38.5288534,09547,489Jan 11 04:19 PM
Klein Matthew B.Chief Operating OfficerJan 07Sale38.5277529,85716,461Jan 11 04:18 PM
Hill Emily LuisaChief Financial OfficerJan 07Sale38.5280030,82022,333Jan 11 04:18 PM
Pauwels EricChief Business OfficerJan 07Sale38.5286633,36334,520Jan 11 04:17 PM
Peltz Stuart WalterChief Executive OfficerJan 07Sale38.5229411,32622,540Jan 11 04:16 PM
Peltz Stuart WalterChief Executive OfficerJan 07Sale38.521,86972,00378,446Jan 11 04:16 PM
Svoronos DawnDirectorJan 07Sale38.5251019,64826,555Jan 11 04:14 PM
Hill Emily LuisaChief Financial OfficerJan 04Sale41.161737,12123,133Jan 06 04:10 PM
Almstead Neil GregoryChief Technical Ops OfficerJan 04Sale41.16642,6341,755Jan 06 04:10 PM
Peltz Stuart WalterChief Executive OfficerJan 04Sale41.1637815,55922,834Jan 06 04:08 PM
Pauwels EricChief Business OfficerJan 04Sale41.1680633,17735,386Jan 06 04:09 PM
Boulding Mark ElliottExec. VP and CLOSep 02Option Exercise18.013,36360,56851,737Sep 03 04:06 PM
Boulding Mark ElliottExec. VP and CLOSep 02Sale45.013,363151,37548,374Sep 03 04:06 PM
Okey StephanieDirectorAug 13Sale40.061,65066,094963Aug 17 04:04 PM
Boulding Mark ElliottExec. VP and CLOJul 09Option Exercise18.011,42925,73648,922Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 09Sale45.001,42964,30648,374Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 08Option Exercise16.277,805127,00850,174Jul 12 04:26 PM
Boulding Mark ElliottExec. VP and CLOJul 08Sale45.227,805352,96848,374Jul 12 04:26 PM